Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Stock Information for Crescent Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescent Biopharma Inc.

Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
Crescent Biopharma Announces Grants of Inducement Awards

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.